

MagVenture announces FDA clearance of Pain Therapy in the US: A non-invasive approach to CHRONIC PAIN relief

ALPHARETTA, GA, UNITED STATES, December 4, 2023 /EINPresswire.com/ -- [MagVenture](#), a renowned global manufacturer of Magnetic Stimulation devices, celebrates a new milestone with the launch of [MagVenture Pain Therapy](#)—an FDA-cleared solution for chronic pain relief. With over 30 years of experience, MagVenture has been at the forefront of using magnetic stimulation to enhance the lives of patients suffering from depression and other psychiatric disorders. Now, with the introduction of MagVenture Pain Therapy, the company is extending its expertise to bring those solutions to chronic pain.



MagVenture Pain Therapy Treatment

“Today, we take all our experience and commitment to patient care to new heights. We're excited about the possibilities of expanding our technology to reach individuals who are living with chronic pain, offering them our perspective on pain management”, says Kerry Rome, Senior Vice President of Sales at MagVenture Inc. He expressed the company's pride in having helped countless patients with depression using their TMS technology over the years.

“

Today, we take all our experience and commitment to patient care to new heights.”

Kerry Rome

MagVenture Pain Therapy employs powerful focused magnetic pulses directed near the injured nerve, providing a non-invasive, painless approach to stimulate peripheral nerves for clinically proven pain relief. Unlike traditional treatments for chronic nerve pain, MagVenture Pain Therapy offers a unique neuromodulation technique.

What sets MagVenture Pain Therapy apart is its versatility and ease of use. Patients can experience relief with sessions lasting just 13 minutes, spread over a two-month period. This

non-pharmacologic treatment is a significant advancement for those seeking a safe, efficient alternative to surgery or medication for chronic pain relief.

For more information about MagVenture Pain Therapy and its potential applications, please visit www.magventurepaintherapy.com.

MagVenture Pain Therapy™ FDA Indications for Use: To stimulate peripheral nerves for relief of chronic intractable, post-traumatic and post-surgical pain for patients 18 years or older

About MagVenture

MagVenture is a market-leading manufacturer of non-invasive Transcranial Magnetic Stimulation (TMS) systems worldwide. Privately owned with headquarters in Denmark, MagVenture has been pioneering leading-edge TMS solutions for more than 30 years. MagVenture's TMS systems are used for both research and treatment in the fields of psychiatry, neurophysiology, neurology, cognitive neuroscience, and rehabilitation.

For more information, please contact:

Kerry Rome, Senior Vice President, MagVenture Inc. (USA) | +1 888 624 7764 | kr@magventure.com

For media inquiries, please contact:

Esben Rosenberg, Global Marketing Manager, MagVenture A/S (DK) | +45 51465592 | ers@magventure.com

Kerry Rome

MagVenture, Inc.

+1 888-624-7764

kr@magventure.com

This press release can be viewed online at: <https://www.einpresswire.com/article/671726965>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.